On this page
COL1A2
collagen type I alpha 2 chain
The COL1A2 gene provides instructions for producing a component of type I collagen, a crucial structural protein found in bones, skin, and other connective tissues throughout the body. COL1A2 encodes the pro-α2(I) chain, which combines with other protein chains to form type I collagen, the most abundant collagen in humans.
COL1A2 is located on the long (q) arm of chromosome 7, at band 7q21.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 7 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The COL1A2 gene provides the genetic blueprint for one of the main components of type I collagen. Type I collagen is a vital structural protein, providing strength and support to a wide array of bodily tissues, including bone, skin, tendons, ligaments, and the sclera of the eye. As the most prevalent type of collagen in the human body, its proper formation is essential for tissue integrity and function.
Changes within the COL1A2 gene can lead to alterations in the structure or quantity of type I collagen. Such alterations can compromise the strength and resilience of connective tissues, resulting in a spectrum of inherited disorders. These conditions often manifest with symptoms affecting the skeletal system and other connective tissue-rich areas.
What the gene does
The primary function of the COL1A2 gene is to direct the synthesis of the pro-α2(I) chain, a key building block of type I collagen. Type I collagen itself is a complex protein assembled from three individual chains that intertwine to form a triple helix structure. Specifically, mature type I collagen is typically composed of two pro-α1(I) chains, which are encoded by the COL1A1 gene, and one pro-α2(I) chain from the COL1A2 gene.
The process begins within cells, where these chains are synthesised and then processed through a series of enzymatic steps. These steps occur both inside and outside the cell, transforming the initial 'procollagen' molecules into mature collagen. Once formed, these collagen molecules assemble into long, thin structures known as fibrils. These fibrils then form stable cross-links with one another in the extracellular space, creating robust type I collagen fibres. These strong fibres are what provide structural integrity and mechanical strength to many connective tissues throughout the body.
Video: Genetics 101
Chromosome location
The COL1A2 gene is located on the long (q) arm of chromosome 7. Its precise genomic address is 7q21.3. This location specifies its position on the chromosome, indicating that it resides on band 21.3 of region 2 on the long arm of chromosome 7. The gene contains multiple exons, which are the coding segments of DNA that are eventually translated into the protein.
Protein structure
The protein produced from the COL1A2 gene, the pro-α2(I) chain, is 1366 amino acids long. This protein exhibits a specific domain organisation crucial for its function in collagen assembly. A significant portion of the protein, spanning amino acids 28 to 1130, is characterised as a Disordered Region. This designation often implies flexibility and involvement in protein-protein interactions, which are vital for the intricate assembly of collagen.
Towards the C-terminus, from amino acids 1133 to 1366, lies the Fibrillar collagen NC1 Domain. This domain is critical for the initial assembly of the three collagen chains into a triple helix and plays a role in the subsequent processing and cross-linking of collagen molecules to form stable fibrils.
Key variants
Variations within the COL1A2 gene can alter the production or structure of the pro-α2(I) chain, thereby affecting the integrity and function of type I collagen. These genetic changes can range from single nucleotide substitutions to larger deletions or duplications of genetic material. Depending on their nature and location within the gene, COL1A2 variants can lead to a spectrum of clinical presentations.
Some variants may result in an abnormally shortened protein, while others might introduce structural defects into the collagen triple helix. The impact of a specific variant often depends on how severely it compromises the ability of type I collagen to form strong, functional fibres, leading to varying degrees of tissue fragility and other symptoms.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1001G>A | p.Gly334Asp | Pathogenic/Likely pathogenic | ★★☆☆ | Osteogenesis imperfecta |
c.1009G>A | p.Gly337Ser | Pathogenic | ★★☆☆ | Osteogenesis imperfecta type I |
c.1035_1035+2del | - | Pathogenic/Likely pathogenic | ★★☆☆ | Osteogenesis imperfecta type III |
c.1045G>A | p.Gly349Ser | Pathogenic | ★★☆☆ | Osteogenesis imperfecta type I |
c.1054G>A | p.Gly352Ser | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.1072G>A | p.Gly358Ser | Pathogenic | ★★☆☆ | not provided |
c.1081G>A | p.Gly361Ser | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.1081G>T | p.Gly361Cys | Pathogenic/Likely pathogenic | ★★☆☆ | Osteogenesis imperfecta |
c.1099G>A | p.Gly367Arg | Pathogenic | ★★☆☆ | Osteogenesis imperfecta type I |
c.1109G>T | p.Gly370Val | Pathogenic | ★★☆☆ | not provided |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the COL1A2 gene are primarily associated with inherited disorders affecting connective tissues. These include various forms of Osteogenesis imperfecta, a group of conditions characterised by fragile bones that are prone to fractures. COL1A2 variants can cause severe forms of osteogenesis imperfecta, such as types II, III, and IV, and occasionally the milder type I. Additionally, certain COL1A2 variants are known to cause Ehlers-Danlos syndrome, specifically the arthrochalasia type, which presents with significant joint hypermobility and dislocations. In some instances, individuals with COL1A2 variants may exhibit features overlapping both osteogenesis imperfecta and Ehlers-Danlos syndrome.
Inheritance pattern
Conditions caused by pathogenic COL1A2 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
In the UK, the COL1A2 gene is included in several NHS Genomic Medicine Service national test directories, reflecting its established clinical significance. It is part of panels for conditions such as Ehlers Danlos syndrome with a likely monogenic cause, Foetal anomalies, Osteogenesis imperfecta, Skeletal dysplasia, and Thoracic aortic aneurysm or dissection. Its inclusion in these 'green' rated panels on PanelApp indicates that there is strong evidence for a gene-disease association and that variants in COL1A2 are considered causative for these conditions within a clinical diagnostic setting.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
Maintaining overall bone health and connective tissue support may be beneficial for individuals with conditions related to COL1A2, though specific lifestyle advice should always come from a healthcare provider. General recommendations for skeletal health include engaging in weight-bearing exercise, which can help promote bone density in the general population. A balanced diet rich in calcium and vitamin D is also widely recognised for its role in bone metabolism. However, these general recommendations do not prevent the genetic basis of COL1A2-related conditions, and their impact may vary significantly depending on the specific condition and individual circumstances.
Supplement considerations
While certain supplements are often discussed in the context of bone and connective tissue health, there is no conclusive evidence that specific supplements can prevent or cure conditions caused by COL1A2 gene variants. Calcium and vitamin D are crucial for bone health, and some individuals with connective tissue disorders may benefit from ensuring adequate intake. However, any decision to take supplements should be made in consultation with a healthcare professional, as excessive intake can have adverse effects and may not be suitable for everyone. Individual needs can vary, and a doctor can provide tailored advice.
Frequently asked questions
What is type I collagen and why is it important?
Type I collagen is the most abundant collagen in the human body. It is a fibrous protein that provides structural strength and support to many tissues, including bones, skin, tendons, and ligaments, helping them withstand stretching and pressure.
What are the main conditions associated with COL1A2 gene variants?
Variants in the COL1A2 gene are primarily associated with osteogenesis imperfecta, characterised by fragile bones, and the arthrochalasia type of Ehlers-Danlos syndrome, which involves joint hypermobility and dislocations. Some individuals may present with features of both conditions.
How does a change in the COL1A2 gene affect collagen?
A change in the COL1A2 gene can alter the pro-α2(I) chain, which is a component of type I collagen. This can lead to collagen that is either poorly formed, structurally weak, or produced in insufficient amounts, compromising the strength and integrity of connective tissues.
Is COL1A2 associated with autosomal dominant inheritance?
Yes, conditions linked to pathogenic variants in COL1A2, such as osteogenesis imperfecta and Ehlers-Danlos syndrome (arthrochalasia type), typically follow an autosomal dominant inheritance pattern. This means only one altered copy of the gene is sufficient to cause the condition.
Can lifestyle changes prevent COL1A2-related conditions?
Lifestyle changes cannot prevent genetically determined conditions caused by COL1A2 variants. However, general healthy lifestyle practices, such as a balanced diet and appropriate exercise, may support overall bone and connective tissue health, though their impact varies individually.
References
- Lim J, Grafe I, Alexander S. Genetic causes and mechanisms of Osteogenesis Imperfecta. Bone. 2017. PMID: 28232077
- Brady AF, Demirdas S, Fournel-Gigleux S. The Ehlers-Danlos syndromes, rare types. American journal of medical genetics. Part C, Seminars in medical genetics. 2017. PMID: 28306225
- Malfait F, Francomano C, Byers P. The 2017 international classification of the Ehlers-Danlos syndromes. American journal of medical genetics. Part C, Seminars in medical genetics. 2017. PMID: 28306229
- Marini JC, Forlino A, Bächinger HP. Osteogenesis imperfecta. Nature reviews. Disease primers. 2017. PMID: 28820180
- Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. American journal of medical genetics. Part A. 2014. PMID: 24715559
- Malfait F, Symoens S, Goemans N. Helical mutations in type I collagen that affect the processing of the amino-propeptide result in an Osteogenesis Imperfecta/Ehlers-Danlos Syndrome overlap syndrome. Orphanet journal of rare diseases. 2013. PMID: 23692737
- Giunta C, Steinmann B. Gene symbol: COL1A2. Disease: Ehlers-Danlos syndrome type VIIB. Human genetics. 2008. PMID: 20960610
- Malfait F, Symoens S, Coucke P. Total absence of the alpha2(I) chain of collagen type I causes a rare form of Ehlers-Danlos syndrome with hypermobility and propensity to cardiac valvular problems. Journal of medical genetics. 2006. PMID: 16816023
- Schwarze U, Hata R, McKusick VA. Rare autosomal recessive cardiac valvular form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway. American journal of human genetics. 2004. PMID: 15077201